PMMA
4-methoxymethamphetamine
Viewing r1 — Apr 25, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
PMMA (para-methoxymethamphetamine) is a synthetic stimulant of the substituted amphetamine class. It is the N-methyl derivative of PMA, sharing its dangerous serotonergic profile. PMMA is a serotonin-preferring monoamine releaser[1] and MAO-A inhibitor,[2] producing its effects by releasing serotonin while blocking the enzyme that degrades it.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
PMMA was first characterised in animals in 1988[3] and documented in Shulgin's PiHKAL (1991) under entry #130.[4] Mass-casualty events — 12 deaths in Norway,[5] 21 in Canada[6] — established PMMA as one of the most dangerous adulterants in the illicit MDMA supply. It is encountered almost exclusively as a fraudulent substitute for MDMA in ecstasy tablets, with no accepted medical use in any jurisdiction.
Subjective effects include tachycardia, compulsive yawning, and eye muscle disturbance — physiological reactions without accompanying euphoria, empathy, or perceptual change.[4] The experience is defined by its absence of reward — the physical burden of a serotonergic stimulant without the entactogenic payoff that users purchasing "ecstasy" expect. Nausea, dangerous hyperthermia, and muscle rigidity are characteristic unsought effects.
No dependence data exist, and the margin between an active and fatal dose is among the narrowest of any recreational drug.[5] The dual mechanism — serotonin release compounded by MAO-A inhibition — creates an additive serotonergic burden that drives lethal hyperthermia,[7] worsened by delayed brain penetration that encourages redosing before peak effects.[8] Understanding rests almost entirely on forensic case series and animal studies; no controlled human trials have been conducted.
History[edit]
Discovery
The first peer-reviewed study of PMMA was conducted by Glennon and colleagues in 1988, who found that the compound failed to produce either amphetamine-like or hallucinogen-like stimulus effects in mice — distinguishing it pharmacologically from both classical stimulants and psychedelic amphetamines.[3] Alexander Shulgin documented PMMA in PiHKAL (1991) under entry #130 as "METHYL-MA," testing it at 110 mg orally and reporting tachycardia, compulsive yawning, and eye disturbance without any psychoactive effect.[4] He explicitly discouraged further human experimentation, citing animal data showing catatonia and "unsuspected neurochemical changes."
Illicit market emergence
PMMA appeared on European drug markets in the late 1990s as pressed tablets sold as "ecstasy," frequently mixed with PMA or MDMA. By 2002, the European Monitoring Centre for Drugs and Drug Addiction had documented 29 seizure incidents involving nearly 19,000 tablets across 15 EU member states, with at least three associated deaths.[9] The EU Council placed PMMA under controls on 28 February 2002 — the first major international scheduling action for the compound.
Mass-casualty events
PMMA's public health significance is defined by a series of mass-casualty incidents linked to ecstasy tablets. The Norwegian "PMMA epidemic" of 2010–2011 killed 12 people and hospitalised 22 more over six months, with the implicated tablets known as "Death".[5] A parallel wave struck western Canada in 2011, producing 21 fatalities across Alberta and British Columbia.[6] Additional deaths have been documented in Germany,[10] the Netherlands, Scotland,citation needed Ireland,citation needed and Argentina — including five deaths at the "Time Warp" event in Buenos Aires in 2016.[11]
The name PMMA derives from its systematic designation as para-methoxy-N-methylamphetamine; Shulgin catalogued it as "METHYL-MA" in PiHKAL, reflecting its structural relationship to MA (PMA). PMMA's precursors — including 4-methoxyphenyl-2-propanone, obtainable from trans-anethole extracted from star anise — are unrestricted chemicals in many jurisdictions,[12] a factor that has repeatedly enabled clandestine production. The compound has no recreational identity of its own; it is known exclusively as a dangerous contaminant of the MDMA supply.
Chemistry[edit]
Structural class
PMMA belongs to the substituted amphetamine family. It is the N-methyl derivative of PMA (para-methoxyamphetamine) and the 4-methoxy analogue of methamphetamine, placing it within the para-methoxy-substituted amphetamine series — a subclass characterised by pronounced serotonergic activity and MAO-A inhibition rather than the dopaminergic stimulation of unsubstituted amphetamines.
Molecular structure
| Molecular formula | C₁₁H₁₇NO |
| Molecular weight | 179.26 g/mol |
The molecule comprises a phenethylamine backbone with an α-methyl group (the amphetamine scaffold), an N-methyl group on the amine nitrogen, and a methoxy substituent at the para (4-) position of the aromatic ring. The methoxy group is the key structural element distinguishing PMMA from Methamphetamine, conferring serotonergic selectivity and MAO-A inhibitory activity.
Stereochemistry
PMMA possesses one chirality centre at the α-carbon. The S(+)-enantiomer is the pharmacologically active form, essentially equipotent with the racemic mixture in drug discrimination studies, while the R(−)-enantiomer fails to produce comparable effects.[13] Clandestine tablets contain racemic PMMA; no enantiopure preparations have been reported in forensic seizures.
Physical properties
No published characterisation of PMMA free base or hydrochloride salt physical properties (melting point, solubility, stability) exists in the reviewed literature. Clandestine PMMA is encountered as the hydrochloride salt in pressed tablet form, frequently co-formulated with PMA, MDMA, or inert excipients.[12]
Pharmacology[edit]
Mechanism of action
PMMA operates through two converging serotonergic mechanisms that together explain its disproportionate lethality relative to MDMA.[7][2]
First, PMMA enters serotonin and norepinephrine transporters as a substrate, triggering non-exocytotic monoamine release with preferential activity at SERT and NET over the DAT.[1][7] This serotonin-preferring release profile aligns PMMA with entactogens rather than classical stimulants.
Second, PMMA inhibits MAO-A — the enzyme responsible for breaking down serotonin, norepinephrine, and dopamine in the synapse.[2] This prevents the normal clearance of serotonin that PMMA itself releases, creating an additive serotonergic burden. The dual mechanism — release plus degradation blockade — underlies the compound's capacity to cause serotonin syndrome and lethal hyperthermia at doses that a simple releaser without monoamine oxidase inhibition would survive.[7][14]
Pharmacokinetics
No controlled human pharmacokinetic studies have been published for PMMA. All available data derive from rat models.
In rats, plasma concentrations peak at approximately 30 minutes, but brain concentrations at higher doses peak at approximately 60 minutes — a significant delay suggesting dose-dependent brain penetration.[8] This creates a pharmacokinetic trap: blood-level effects appear to wane before full central nervous system action develops, encouraging redosing before peak brain effects. PMMA distributes extensively into tissues, with a brain-to-plasma ratio reaching approximately 16 at eight hours.[15]
The primary metabolic pathway is O-demethylation, with CYP2D6 as the dominant enzyme.[16] Individuals who are CYP2D6 poor metabolizers clear the drug significantly more slowly and face elevated toxicity risk at any dose. PMMA also undergoes renal excretion via the organic cation transporter OCT2;[17] natural genetic variation in OCT2 may contribute to individual differences in elimination.
Neuroscience[edit]
Where it acts
PMMA elevates serotonin and dopamine in the striatum, nucleus accumbens, and frontal cortex.[14] A distinctive pattern distinguishes it from MDMA: PMMA increases serotonin tissue content in the striatum while simultaneously decreasing cortical dopamine — a dissociation that may contribute to its comparatively weaker subjective effects.
The environment-dependent nature of PMMA's most dangerous effect has been demonstrated in rats: hyperthermia occurred only under crowded conditions, not in isolated housing.[8] This parallels the rave and dance settings in which most human PMMA fatalities have occurred, implicating ambient temperature, physical exertion, and crowding as critical modulators of lethal potential.
Neurotoxicity
PMMA causes dopaminergic neuron loss in the striatum through activation of protein kinase C delta (PKCδ), which translocates to mitochondria and triggers a cascade of oxidative stress, mitochondrial dysfunction, microglial activation, and inflammatory signalling.[18] Mice lacking either PKCδ or TNF-α were protected from this damage, establishing these as necessary mediators of PMMA neurotoxicity.[18] This mechanism is distinct from MDMA neurotoxicity, which primarily damages serotonergic rather than dopaminergic neurons.
Whether PMMA produces entactogenic effects in humans at any dose remains unanswered — Shulgin reported no psychoactivity at 110 mg,[4] yet animal data place PMMA in the MDMA-like stimulus class. Whether single human exposures cause the dopaminergic neuron loss demonstrated in mouse models[18] is unknown.
Subjective Effects[edit]
PMMA's experiential profile is dominated by physiological activation rather than subjective psychoactivity. The only controlled human account — Shulgin's self-experiment at 100–110 mg[4] — described cardiovascular stress and somatic discomfort without euphoria, empathy, or perceptual alteration. Set and setting have limited influence on an experience that lacks central psychoactivity at sub-toxic doses; the slow onset relative to MDMA is the most consequential feature, as it encourages redosing before peak action develops.
Compared to MDMA, PMMA delivers the physical cost of an entactogen without the experiential reward. Animal drug discrimination data classify PMMA in the MDMA-like stimulus class,[19] but this pharmacological similarity has not translated into confirmed empathogenic effects in humans at any documented dose. Where MDMA produces warmth, openness, and connection, PMMA produces tachycardia, yawning, and somatic distress.
Effect Grid
At common doses (100–120 mg oral), the full PMMA experience — such as it is — manifests primarily as physiological activation rather than psychoactivity. Tachycardia (pulse exceeding 100 bpm), compulsive yawning, and eye muscle disturbance resembling nystagmus were documented at 110 mg by Shulgin. No euphoria, empathy enhancement, or perceptual effects were reported.
Physical effects dominate: elevated heart rate and blood pressure, excessive sweating, possible bruxism, and pupil dilation. The onset is notably slow (estimated 45–90 minutes), and the disconnect between peripheral effects and absent central psychoactivity is characteristic. Total duration is approximately 3–5 hours.
The slow onset at this range is the most dangerous feature — users expecting MDMA-like effects within 30 minutes may redose before PMMA's full action develops, pushing total intake into the lethal range.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual drifting · Tracers
Dehydration sensation · Wakefulness · Pupil dilation · Vasoconstriction · Body high · Dry mouth · Heart rate perception changes · Insomnia · Restlessness · Dizziness · Bruxism · Sexual arousal suppression · Nausea · Muscle tension · Spontaneous body sensations · Seizure threshold reduction · Headache · Tactile euphoria · Tingling / electric sensations · Trembling · Vomiting
Body high · Dry mouth · Heart rate perception changes · Insomnia · Restlessness · Dizziness · Bruxism · Sexual arousal suppression · Nausea · Muscle tension · Spontaneous body sensations · Seizure threshold reduction · Headache · Tactile euphoria · Tingling / electric sensations · Trembling · Vomiting
Thought acceleration · Thought disorganization
Trust enhancement
Timeline
First perceptible effects: subtle increase in heart rate, mild restlessness. Onset is notably slower than MDMA, a critical distinction — the delay drives dangerous redosing behaviour.
Sympathomimetic activation builds: tachycardia becomes distinct, blood pressure rises, possible onset of sweating and jaw tension. Central psychoactive effects remain absent or minimal at common doses.
Maximum physiological activation: tachycardia (pulse >100 bpm), compulsive yawning, eye muscle disturbance. At 110 mg, Shulgin described physical effects resembling MDMA's body load without euphoria or empathogenic character.
Gradual return to baseline. Cardiovascular effects subside over 1–2 hours. Shulgin reported full resolution by approximately hour 4 at 110 mg.
Residual fatigue and possible mild malaise. No specific afterglow data published for PMMA.
⚠ Avoid driving or operating machinery for at least 6 hours after ingestion, as residual cardiovascular and cognitive effects may persist beyond subjective resolution.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- MDMA · PMA · amphetamine
Toxicity
Acute toxicity
PMMA carries critical acute toxicity risk. Over 40 deaths have been documented internationally, many from single-tablet ingestions. The margin between non-fatal and fatal blood concentrations is barely one order of magnitude.[5]
PMMA has caused over 40 documented deaths internationally. Fatal outcomes have occurred from single-tablet ingestions. The margin between active and lethal doses is extremely narrow, and there is no established safe dose range.
Death follows a characteristic trajectory: agitation and autonomic instability escalate to dangerous hyperthermia (body temperatures exceeding 40°C), seizures, cardiovascular collapse, and multi-organ failure.[5][6] Kidney failure has been documented in survivors.
Emergency treatment is supportive: aggressive cooling for hyperthermia, benzodiazepines for seizures and agitation, cyproheptadine for serotonin syndrome features. There is no specific antidote.
Polydrug synergistic toxicity
Polydrug use was present in the majority of Norwegian fatal cases.[5] PMMA combined with depressants (alcohol, opioids, benzodiazepines) produced fatalities at notably lower PMMA blood concentrations than PMMA alone, suggesting depressants mask early warning signs of toxicity while the hyperthermic mechanism progresses unchecked.
Neurotoxicity
PMMA causes dopaminergic neuron loss in the striatum of mice through a PKCδ–TNF-α-mediated mitochondrial stress pathway.[18] Whether single human exposures produce lasting brain damage has not been established.
Psychological risks
Systematic data on PMMA-specific psychological risks are absent. Shulgin reported no psychoactive effects at 110 mg.[4] In fatal and near-fatal cases, agitation and delirium are documented as features of serotonin syndrome,[5] but these are medical emergencies rather than primary psychological effects.
Animal data suggest PMMA may disrupt sensorimotor gating,[8] which could produce disorganised cognition at active doses, but no human data confirm this. No data exist on lasting psychological effects, psychosis precipitation, or psychiatric destabilisation following PMMA exposure.
Tolerance & dependence
No published data exist on PMMA-specific tolerance, cross-tolerance, or dependence in humans or animals. As a serotonin-preferring releaser with weak dopaminergic activity, PMMA would be expected by class analogy with MDMA to have low reinforcement potential — but this is structural inference, not direct evidence.[14]
Drug interactions
PMMA's dual mechanism — serotonin release plus MAO-A inhibition — creates a uniquely dangerous interaction profile. Any co-administered serotonergic agent adds to an already elevated serotonergic burden.
Serotonergic combinations
Combination with any serotonin-active drug carries severe serotonin syndrome risk. Documented fatal combinations include PMMA with MDMA,[5][6] PMA,[10][9] and amphetamine. SSRIs, SNRIs, and MAOIs carry class-inferred extreme risk.
CYP2D6 inhibitors
PMMA is primarily metabolised by CYP2D6.[16] Co-administration of CYP2D6 inhibitors — including fluoxetine, paroxetine, bupropion, haloperidol, and ritonavir — could reduce PMMA clearance and elevate blood concentrations into the lethal range. Fluoxetine and paroxetine are both CYP2D6 inhibitors and serotonergic agents, compounding the risk through two independent mechanisms.
CNS depressants
PMMA combined with depressants (alcohol, opioids, benzodiazepines) produced fatalities at lower PMMA concentrations than PMMA alone in the Norwegian case series.[5] Depressants may mask the early agitation and autonomic warning signs of developing serotonin syndrome, allowing hyperthermia to progress undetected.
Stimulants
Co-ingestion of cocaine, amphetamine, or methamphetamine carries additive cardiovascular and hyperthermia risk.[6] Multiple synthetic amphetamines were co-present in the majority of Canadian fatalities.
Contraindications
Absolute contraindications
- MAOI therapy: Combining exogenous monoamine oxidase inhibition with PMMA's own MAO-A inhibition creates a near-certain serotonin syndrome scenario
- SSRI/SNRI therapy: The combination of serotonin release, MAO-A inhibition, and reuptake inhibitor produces extreme serotonergic overload
- CYP2D6 poor metabolizer status: Genetically impaired clearance increases blood concentrations and toxicity risk at any dose[16]
Relative contraindications
- Pre-existing heart conditions: PMMA produces tachycardia and sympathomimetic cardiovascular stress[4][20]
- High blood pressure and hyperthyroidism: Sympathomimetic activity may worsen underlying conditions[20][21]
- Liver impairment: May reduce metabolic clearance, compounding CYP2D6-dependent elimination
- Kidney impairment: OCT2-mediated renal excretion[17] may be compromised, reducing drug elimination
- Pregnancy: Contraindicated on general pharmacological grounds as a sympathomimetic monoamine releaser
Harm Reduction[edit]
Forms & Identification
PMMA is encountered almost exclusively as pressed tablets sold as "ecstasy" or "MDMA," often co-formulated with PMA, MDMA, or other synthetic amphetamines.[12] Because PMMA tablets are visually indistinguishable from legitimate MDMA tablets, reagent testing alone is insufficient — standard colorimetric kits can indicate the presence of a substance class but cannot reliably differentiate PMMA from MDMA. Quantitative drug checking services or laboratory-grade analysis (GC-MS, FTIR) provide the only reliable identification.
Guidelines
- Test every tablet using a drug checking service with quantitative capability — reagent kits alone cannot reliably distinguish PMMA from MDMA
- Never redose based on MDMA timing expectations — PMMA's onset is significantly slower; wait at least 2–3 hours before concluding a dose is inactive
- Stay cool — avoid prolonged dancing, hot environments, and crowding; take regular breaks in cool areas and drink water at a moderate pace
- Disclose all medications — anyone taking antidepressants, antipsychotics, or HIV antiretrovirals (particularly CYP2D6 inhibitors) faces elevated risk from any dose
- Never use alone — ensure someone present is aware of what was taken and knows the signs of serotonin syndrome
Set & Setting
The majority of PMMA fatalities have occurred in crowded, hot environments — raves, clubs, and festivals — where ambient temperature, physical exertion, and dehydration compound the compound's hyperthermic toxicity.[8] PMMA's slow onset relative to MDMA creates a dangerous mismatch with these environments: users are most likely to redose in settings where the consequences of double-dosing are most severe.
Aftercare & integration. PMMA exposure — whether intentional or accidental — is a physically taxing event dominated by cardiovascular and thermoregulatory stress. In the hours and days following exposure, prioritise rest, hydration, and gradual temperature regulation.
Monitor for delayed symptoms including muscle pain, dark urine (which may indicate kidney stress), or persistent elevated heart rate, and seek medical attention if any appear. PMMA does not produce the cognitive or emotional experiences associated with entactogens at sub-toxic doses, so there is no meaningful integration component in the psychedelic sense.
Recovery & Support
PMMA is not associated with physical dependence or compulsive use patterns. Repeated exposure is rare because most encounters are accidental — PMMA sold as MDMA — and the experience is unrewarding. If PMMA exposure is part of a broader pattern of stimulant or MDMA use, harm reduction services, peer support networks, and substance use counselling can address the underlying use pattern rather than PMMA specifically.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: body temperature you can feel through clothing, rigid muscles, seizures, confusion or delirium, loss of consciousness, or a rapid heart rate that does not settle with rest. Any of these after suspected PMMA ingestion is a medical emergency.
Immediate steps:
- Call emergency services immediately.
- Move the person to the coolest available environment.
- Remove excess clothing and apply cold water or ice packs to the neck, armpits, and groin.
- If unconscious but breathing, place in the recovery position.
- Do not induce vomiting. Do not give aspirin or paracetamol for fever — these do not work on drug-induced hyperthermia.
- Stay with the person until help arrives.
What to tell the dispatcher: The substance (suspected PMMA or PMA in an ecstasy tablet), the amount taken, when it was taken, and current symptoms — especially body temperature and seizure activity. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
PMMA is controlled in all major jurisdictions. The EU Council first placed it under international control in February 2002,[9] and it was added to Schedule I of the United Nations 1971 Convention on Psychotropic Substances in March 2016.[22] PMMA has no accepted medical use in any jurisdiction.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Placed in Schedule I effective 26 July 2021 by DEA final rule.[22] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled as a methamphetamine derivative.[11] |
| Canada | Schedule I (Controlled Drugs and Substances Act) | Prohibited; no permitted medical use.[11] |
| European Union | Controlled (Council Decision, 28 February 2002) | All EU member states required to implement controls following 29 seizure incidents across 15 states.[9] |
| Germany | Anlage I (BtMG) | Controlled; authorised scientific use only.[11] |
| Brazil | F2 list | Controlled.[11] |
| Australia | Prohibited (schedule unconfirmed) | Classified as prohibited by the Alcohol and Drug Foundation;[20] specific Poisons Standard entry not confirmed.citation needed |
| United Nations | Schedule I (1971 Convention on Psychotropic Substances) | Added at 59th CND session, March 2016.[22] |
references
- [1] ^abSimmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones — Neuropharmacology doi:10.1016/j.neuropharm.2013.11.008
- [2] ^abcReyes-Parada M, Iturriaga-Vasquez P, Cassels BK (2019) Amphetamine Derivatives as Monoamine Oxidase Inhibitors — Frontiers in Pharmacology doi:10.3389/fphar.2019.01590
- [3] ^abGlennon RA, Ismaiel AE, Martin B, Poff D, Sutton M (1988) A preliminary behavioral investigation of PMMA, the 4-methoxy analog of methamphetamine — Pharmacology, Biochemistry, and Behavior PMID:3252264
- [4]
- [5]
- [6]